rucaparib has been researched along with 4-hydroxyquinazoline* in 1 studies
1 other study(ies) available for rucaparib and 4-hydroxyquinazoline
| Article | Year |
|---|---|
Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
The effective potency and resistance of poly(ADP-ribose) polymerase (PARP) inhibitors limit their application. Here, we exploit a new paradigm that mimics the effects of breast cancer susceptibility genes (BRCA) mutations to trigger the possibility of synthetic lethality, based on the previous discovery of a potential synthetic lethality effect between bromodomain-containing protein 4 (BRD4) and PARP1. Consequently, the present study describes compound Topics: Antineoplastic Agents; BRCA1 Protein; Cell Cycle Proteins; Cell Line, Tumor; Homologous Recombination; Humans; Nuclear Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolinones; Synthetic Lethal Mutations; Transcription Factors; Triple Negative Breast Neoplasms | 2022 |